Brigitte Malgrange – VJRegenMed https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Fri, 21 Jan 2022 11:15:12 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png Brigitte Malgrange – VJRegenMed https://mirror.vjregenmed.com 32 32 Elucidating mechanisms of hearing loss with iSPCs https://mirror.vjregenmed.com/video/ymej80jb1la-elucidating-mechanisms-of-hearing-loss-with-ispcs/ Tue, 04 Jan 2022 13:03:22 +0000 http://13.40.107.223/video/ymej80jb1la-elucidating-mechanisms-of-hearing-loss-with-ispcs/ Brigitte Malgrange, Pharm.D, PhD, University of Liège, Liège, Belgium, describes ongoing research to develop organoids and bioassays for researching hereditary hearing loss. Over 100 genes are implicated in hereditary hearing loss and sourcing induced pluripotent stem cells (iSPCs) derived from fibroblasts are important to determine the mechanisms of the disease. Dr Malgrange additionally highlights the possibility of developing regenerative therapies as a result of the aforementioned research conducted. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).

]]>
Addressing issues with developing therapies for hearing loss https://mirror.vjregenmed.com/video/sb8hajkh1ie-addressing-issues-with-developing-therapies-for-hearing-loss/ Tue, 04 Jan 2022 13:03:21 +0000 http://13.40.107.223/video/sb8hajkh1ie-addressing-issues-with-developing-therapies-for-hearing-loss/ Brigitte Malgrange, Pharm.D, PhD, University of Liège, Liège, Belgium, provides an overview of the current challenges associated with generating regenerative therapies for hearing loss. Numerous advancements have been made in the field and therapies based on induced pluripotent stem cells (iSPCs) are becoming more feasible as a result. However, the complex structure of the inner ear results in making the ear less accessible for therapies compared to other areas such as the eye. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).

]]>